Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin

Histology and Histopathology

Volumn 25, Issue 3, 2010, Pages 299-307

  Peroukides, Stavros ^a   Bravou, Vasiliki ^a   Alexopoulos, Alexandros ^a   Varakis, John ^a   Kalofonos, Haralabos ^b   Papadaki, Helen ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Cirrhosis; E cadherin; Hepatocellular carcinoma; P STAT3; Survivin

Indexed keywords

BETA CATENIN; BIRC5 PROTEIN, HUMAN; CADHERIN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN KINASE B; STAT3 PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CHI SQUARE DISTRIBUTION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

APOPTOSIS; BETA CATENIN; CADHERINS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; STAT3 TRANSCRIPTION FACTOR; STATISTICS, NONPARAMETRIC;

EID: 77749342725     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Adida C., Crotty P., McGrath J., Berrebi D., Diebold J. and Altieri D. (1998). Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43-49.
2. Altieri D. (2003a). Survivin in apoptosis control and cell cycle regulation in cancer. Progress in Cell Cycle Res. 5, 447-452.
3. Altieri D. (2003b). Validating survivin as a cancer therapeutic target. Nat. Rev. 3, 46-54.
4. Altieri D. (2006). The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Cur. Opin. Cell Biol. 18, 609- 615.
5. Blanc-Brude O., Mesri M., Wall N., Plescia J., Dohi T. and Altieri D. (2003). Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumorassociated angiogenesis. Clin. Cancer Res. 9, 2683-2692.
6. Chau G-Y., Lee AF-Y., Tsay S-H., Ke Y-R., Kao H-L., Wong F-H., Tsou A-P. and Chau Y-P. (2007). Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 51, 204-218.
7. Costa R.H., Kalinichenko V.V., Holterman A.X. and Wang X. (2003). Transcription factors in liver development, differentiation, and regeneration. Hepatology 38, 1331-1347.
8. Deguchi M., Shiraki K., Inoue H., Okano H., Ito T., Yamanaka T., Sugimoto K., Sakai T., Ohmori S., Murata K., Furusaka A., Hisatomi H. and Nakano T. (2002). Expression of survivin during liver regeneration. Biochem. Biophys. Res. Commun. 297, 59-64.
9. Fields A., Cotsonis G., Sexton D., Santoianni R. and Cohen C. (2004). Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod. Pathol. 17, 1378-1385.
10. Fuke H., Shiraki K., Sugimoto K., Tanaka J., Beppu T., Yoneda K., Yamamoto N., Ito K., Masuya M. and Takei Y. (2007). Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 363, 738-744.
11. Gotoh J., Obata M., Yoshie M., Kasai S. and Ogawa K. (2003). Cyclin D1 over-expression correlates with β-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3, and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 24, 435-442.
12. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D., Yoder S., Enkemann S., Eschrich S., Lee J.H., Beam C.A., Cheng J., Minton S., Muro-Cacho C.A. and Jove R. (2006). Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12, 11- 19.
13. Guo R.P., Zhong C., Shi M., Zhang C.Q., Wei W., Zhang Y.Q. and Li J.Q. (2006). Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 132, 547-555.
14. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., Takase K., Moriyama M., Kawano H., Hayashida M., Nakano T. and Suzuki A. (2000). Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31, 1080-1085.
15. Iurlaro M., Demontis F., Corada M., Zanetta L., Drake C., Gariboldi M., Peiro S., Cano A., Navarro P., Cattelino A., Tognin S., Marchisio P.C. and Dejana E. (2004). VE-Cadherin expression and clustering maintain low levels of survivin in endothelial cells. Am. J. Pathol. 165, 181-189.
16. Johnson M.E. and Howerth E.W. (2004). Survivin: A bifunctional inhibitor of apoptosis protein. Vet. Pathol. 41, 599-607.
17. Kannangai R., Wang J., Liu Q.Z., Sahin F. and Torbenson M. (2005). Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int. J. Gastrointest. Cancer 35, 53-60.
18. Kennedy S.M., O'Driscoll L., Purcell R., Fitz-Simons N., McDermott E.W., Hill A.D., O'Higgins N.J., Parkinson M., Linehan R. and Clynes M. (2003). Prognostic importance of survivin in breast cancer. Br. J. Cancer 88, 1077-1083.
19. Kim P.J., Plescia J., Clevers H., Fearon E.R. and Altieri D.C. (2003). Survivin and molecular pathogenesis of colorectal cancer. Lancet 362, 205-209.
20. Lee S., Lee H.J., Kim J.H., Lee H.S., Jang J.J. and Kang G.H. (2003). Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 163, 1371-1378. (Pubitemid 37175085)
21. Li F. (2003). Survivin study: What is the next wave? J. Cell Physiol. 197, 8-29.
22. Li F., Yang J., Ramnath N., Javle M. and Tan D. (2005). Nuclear or cytoplasmic expression of survivin: What is the significance? Int. J. Cancer 114, 509-512.
23. Li W.C., Ye S.L., Sun R.X., Liu Y.K., Tang Z.Y., Kim Y., Karras J.G. and Zhang H. (2006). Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting Signal Transducer and Activator of Transcription 3. Clin. CancerRes. 12, 7140-7148.
24. Llovet J., Chen Y., Wurmbach E., Roayaie S., Isabel Fiel M., Schwartz M., Thung S.N., Khitrov G., Zhang W., Villanueva A., Battiston C., Mazzaferro V., Bruix J., Waxman S. and Friedman S.L. (2006). A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131, 1758-1767.
25. Lu X.Y., Lee M., Tran T. and Block T. (2005). High levels expression of apoptosis inhibitor in hepatoma cell line expressing hepatitis B virus. Int. J. Med. Sci. 2, 30-35.
26. Mangnall D., Bird N.C. and Majeed A.W. (2003). The molecular physiology of liver regeneration following partial hepatectomy. Liver Int. 23, 124-138.
27. McGlynn K.A. and London W.T. (2005). Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 19, 3-23.
28. Mirza A., McGuirk M., Hockenberry T., Wu Q., Ashar H., Black S., Wen S., Wang L., Kirschmeier P., Bishop W., Nielsen L., Pickett C. and Liu S. (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21, 2613-2622.
29. Moon W.S. and Tarnawski A. (2003). Nuclear translocation of survivin in hepatocellular carcinoma: A key to cancer cell growth? Hum. Pathol. 34, 1119-1126.
30. Morinaga S., Nakamura Y., Ishiwa N., Yoshikawa T., Noguchi Y., Yamamoto Y., Rino Y., Imada T., Takanashi Y., Akaike M., Sugimasa Y. and Takemiya S. (2004). Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol. Rep. 12, 1189-1194.
31. Okada E., Murai Y., Matsui K., Isizawa S., Cheng C., Masuda M. and Takano Y. (2000). Survivin expression in tumor cell nuclei is predictive of a favourable prognosis in gastric cancer patients. Cancer Lett. 163, 109-116.
32. Peroukides S., Bravou V., Varakis J., Alexopoulos A., Kalofonos H. and Papadaki H. (2008). ILK overexpression in human hepatocellular carcinoma and liver cirrhosis correlates with activation of Akt. Oncol. Rep. 20, 1337-1344.
33. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., Morimoto S., Iida M. and Sasaguri T. (2007). Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol. 73, 1318-1329.
34. Starkel P., Bishop K., Horsmans Y. and Strain A.J. (2003). Expression and DNA-binding activity of Signal Transducer and Activator of Transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans. Am. J. Pathol. 162, 587-596.
35. Starkel P., DeSaeger C., Leclercq I. and Horsmans Y. (2007). Role of signal transducer and activator of transcription 3 in liver fibrosis progression in chronic hepatitis C-infected patients. Lab. Invest. 87, 173-181.
36. Takashima H., Nakajima T., Moriguchi M., Sekoguchi S., Nishikawa T., Watanabe T., Katagishi T., Kimura H., Minami M., Itoh Y., Kagawa K. and Okanoue T. (2005). In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int. 25, 77-84.
37. Taub R. (2003). Hepatoprotection via the IL-6/Stat3 pathway. J. Clin. Invest. 112, 978-980.
38. Torres V.A., Tapia J.C., Rodriguez D.A., Lladser A., Arredondo C., Leyton L. and Quest A.F. (2007). E-Cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced β-catenin-Tcf/Lef-dependent transcription. Mol. Cel. Biol. 27, 7703-7717.
39. Tringler B., Lehner R., Shroyer A.L. and Shroyer K.R. (2004). Immunohistochemical localization of survivin in serous tumors of the ovary. Appl. Immunohistochem. Mol. Morphol. 12, 40-43.
40. Wang J., Yang L., Yang J., Kuropatwinski K., Wang W., Liu X.Q., Hauser J. and Brattain M.G. (2008). Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3 kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 68, 3152-3160.
41. Yoshida T., Hanada T., Tokuhisa T., Kosai K., Sata M., Kohara M. and Yoshimura A. (2002). Activation of STAT3 by the Hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196, 641- 653.
42. Zhang T., Otevrel T., Gao Z., Gao Z., Ehrlich S., Fields J. and Boman B. (2001). Evidence that APC regulates survivin expression: A possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 62, 8664-8667.
43. Zhihong A., Lianhua Y., Xianrong Z., Ying Z., Dongmei Z., Yinhua Y. and Youji F. (2006). Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107, 746-756.